BerGenBio ASA

Oslo Stock Exchange BGBIO.OL

BerGenBio ASA Net Cash Used Provided By Financing Activities for the year ending December 31, 2023: USD 22.08 M

BerGenBio ASA Net Cash Used Provided By Financing Activities is USD 22.08 M for the year ending December 31, 2023, a 7,357.20% change year over year. Net cash used/provided by financing activities are the total cash inflows and outflows related to activities that finance the company’s operations, including debt, equity, and dividends.

BerGenBio ASA Net Cash Used Provided By Financing Activities for the year ending December 31, 2022 was USD 296.06 K, a -83.66% change year over year.
BerGenBio ASA Net Cash Used Provided By Financing Activities for the year ending December 31, 2021 was USD 1.81 M, a -97.78% change year over year.
BerGenBio ASA Net Cash Used Provided By Financing Activities for the year ending December 31, 2020 was USD 81.52 M, a 825.94% change year over year.
BerGenBio ASA Net Cash Used Provided By Financing Activities for the year ending December 31, 2019 was USD 8.80 M, a -56.98% change year over year.

Key data

Date	Net Cash Used Provided By Financing Activities	Dividends Paid	Capital Expenditure	Effect Of Forex Changes On Cash

Oslo Stock Exchange: BGBIO.OL

BerGenBio ASA

CEO	Mr. Martin Olin
IPO Date	April 7, 2017
Location	Norway
Headquarters	Jonas Lies vei 91
Employees	15
Sector	Healthcare
Industries Biotechnology Clinical Trials Pharmaceuticals Vaccines

Description

BerGenBio ASA, a clinical-stage biopharmaceutical company, engages in development of drugs to treat immune evasive, drug resistant, and metastatic cancers; and respiratory diseases. Its lead candidate is Bemcentinib, a bio-available small molecule AXL inhibitor, which is in Phase II clinical development in major cancer indications and COVID-19. Its Phase II clinical trial program focuses on treatment of non-small cell lung cancer, acute myeloid leukaemia, and myelodysplastic syndrome, as well as COVID-19. In addition, it is developing tilvestamab, an anti-AXL antibody that is in Phase Ib clinical trial. BerGenBio ASA has a collaboration agreement with Merck & Co. for clinical trials. The company was incorporated in 2007 and is based in Bergen, Norway.

Key trends

Past 5 years